CD86 and colorectal carcinoma: In CRC patients receiving adjutant chemotherapy, patients with a low CD86/CD163 ratio had shorter RFS (HR=0.258, 95% CI=0.145-0.458; p<0.001) and OS (HR=0.170, 95% CI=0.082-0.356; p<0.001) than patients with a high CD86/CD163 ratio.